𝗟𝗶𝗾𝘂𝗶𝗱 𝗯𝗶𝗼𝗽𝘀𝘆 𝗶𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗵𝗲𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗣𝗥𝗘𝗗𝗜-𝗟𝗬𝗡𝗖𝗛 𝗺𝗶𝘀𝘀𝗶𝗼𝗻. 𝗕𝘂𝘁 𝗵𝗼𝘄 𝗱𝗼𝗲𝘀 𝗶𝘁 𝘄𝗼𝗿𝗸?
As cancer develops, it can leave behind tiny molecular traces, such as fragments of tumour DNA, in bodily fluids.
➡ Liquid biopsy technologies are designed to detect and analyse these signals through minimally invasive or non-invasive samples, helping researchers better understand cancer risk and early disease development.
In PREDI-LYNCH, they are exploring innovative approaches to support earlier detection of Lynch syndrome-associated cancers, with the ambition of making screening more accurate, accessible and patient-friendly.
By advancing non-invasive tools and combining molecular analysis with artificial intelligence, PREDI-LYNCH aims to contribute to improved hereditary cancer prevention across Europe.
Lynch Syndrome Ireland 